Immune-Related Adverse Events—A Novel Prediction of Nivolumab Efficacy?

To the Editor Based on a retrospective study, Haratani et al recently revealed that the occurrence of immune-related adverse events (irAEs) could potentially predict the survival benefit in patients with advanced/recurrent non–small cell lung cancer receiving nivolumab.

https://ift.tt/2LbM3Lc